Skip to main
RXST
RXST logo

RxSight (RXST) Stock Forecast & Price Target

RxSight (RXST) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

RxSight Inc has demonstrated a robust gross margin of 71.6%, reflecting a significant increase of 980 basis points year-over-year, surpassing market expectations. The company's Light Adjustable Lens (LAL) revenue reached $28.5 million, marking a strong 60% year-over-year growth, while Light Delivery Device (LDD) revenue grew modestly by 7% to $10.7 million. The increasing monthly utilization of LALs per LDD illustrates an upward trend, supporting the potential for sustained double-digit growth driven by an expanding installed base and improved operational metrics.

Bears say

The financial excerpts reflect a concerning trend for RxSight Inc., with LAL utilization growth slowing significantly to +9% year-over-year in the fourth quarter of 2024, down from the previously reported +17%-22% growth range over the prior five quarters. Additionally, US intraocular lens sales appeared flat or declining, potentially due to a weakening cataract surgery market and increased competition, which may have contributed to the overall slowdown in utilization. Lastly, revised earnings per share estimates for 2025 and 2026 indicate a deterioration in financial expectations, alongside highlighted risks such as limited adoption of new technologies, disappointing commercial performance, and potential for dilutive financing rounds, all of which compound the negative outlook.

RxSight (RXST) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of RxSight and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About RxSight (RXST) Forecast

Analysts have given RxSight (RXST) a Buy based on their latest research and market trends.

According to 12 analysts, RxSight (RXST) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

RxSight (RXST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.